# Clinical Presentation and Outcome of Active Pulmonary Tuberculosis patients requiring Respiratory Intensive Care admission

#### **Thesis**

Submitted for partial fulfillment of the Master Degree in Chest Diseases and Tuberculosis

Presented by

**Mourad Fouda Bendary** 

M.B.B.CH

Supervised by

**Prof. Mona Mansour Ahmed** 

Professor of Pulmonary Medicine

Faculty of Medicine

Ain shams University

#### Dr. Ashraf Mokhtar Madkour

Assistant Professor of Pulmonary Medicine

Faculty of Medicine

Ain shams University

Faculty of medicine, Ain shams University, 2014

# بَيْنِ الْمُرْكِينِ الْمُرْكِينِ الْمُرْكِينِ الْمُرْكِينِ الْمُرْكِينِ الْمُرْكِينِ الْمُرْكِينِ الْمُرْكِينِ

# قَالُواْ سُبْحَننك لَاعِلْمَ لَنَا إِلَّا مَاعَلَمْتَنَا إِنَّكَ أَنتَ ٱلْعَلِيمُ ٱلْحَكِيمُ

صَّابُ وَاللَّهُ الْعُظَمِينَ،

سورة البقرة آية (32)

#### A cknowledgment

First and for most, thanks to **ALLAH** for all of his blessings and for granting me the ability to finish this work.

I am deeply indebted to my supervisor; **Prof. Mona Mansour Ahmed;** Professor of Chest Diseases, Ain Shams
University whose guidance and instructions were invaluable.

I would like to express my gratitude to **Dr. Ashraf Mokhtar Madkour;** assist professor of Chest Diseases, Ain
Shams University for his help and patience all through the time of the research.

I forward my appreciation to all the staff of Chest department of Aim Shams University and Abbassia Chest Hospital; doctors and nurses for their tremendous efforts to help me to finish this research.

## List of Contents

· Introduction	1
· Aim of the work	3
· Review of literature	
1. Historical background	4
2. Epidemiology	6
3. Pathology of tuberculosis	14
4. Diagnosis of tuberculosis	25
5. Comorbidites with TB	46
6. Treatment of tuberculosis	51
7. Multi-drug resistance of tuberculosis	64
8. Patients with active pulmonary tuberculosis requiring ICU admission	76
· Patients and methods	84
D 1/	01
· Results	91
· Discussion	114
· Summary	121
· conclusion	123
· Recommendations	124
· References	125
· Arabic Summary	

## List of tables

Table number	subject	Page
1	Estimates of the burden of the disease caused by TB in Egypt	10
2	Incidence, notification and case detection rates in Egypt	10
3	New smear positive cases as a treatment outcome in Egypt	11
4	Retreatment cases as a treatment outcome in Egypt	11
5	HIV testing and provision of CPT, ART and IPT in Egypt	11
6	Testing for MDR-TB and number of confirmed cases of MDR-TB in Egypt	12
7	New smear-positive case notification by age and sex in Egypt	12
8	First-line anti-tuberculous drugs	51
9	The mode of action and side effects of first-line anti- tuberculous drugs	52
10	Different patient categories and the corresponding treatment category used to treat them	52
11	Side effects of anti TB drugs and their management	59
12	The definitions of different expected outcomes	62
13	Number of bacilli required for the appearance of a mutant resistant to different anti-tuberculous drugs	66
14	Estimated bacterial populations within different TB lesions	67
15	Comparison between survivors and non-survivors as regards demographic characteristics	92

# $\underline{\textit{List of tables}} (\texttt{Cont.})$

Table number	subject	Page
16	Comparison between survivors and non-survivors as regards comorbidities	93
17	Comparison between survivors and non-survivors as regards history of pulmonary tuberculosis infection	94
18	Comparison between survivors and non-survivors as regards vital signs on admission	95
19	Comparison between survivors and non-survivors as regards radiological characteristics pulmonary tuberculosis	96
20	Comparison between survivors and non-survivors as regards to respiratory failure	97
21	Comparison between survivors and non-survivors as regards mechanical ventilation	98
22	Comparison between survivors and non-survivors as regards timing of admission and length of stay in ICU	98
23	Comparison between survivors and non-survivors as regards GSC and APACHE II score on admission	100
24	Comparison between survivors and non-survivors as regards causes of ICU admission	101
25	Comparison between survivors and non-survivors as regards ICU complications	102
26	Comparison between survivors and non-survivors as regards laboratory investigations on admission	104
27	Comparison between survivors and non-survivors as regards to ABG on admission	105
28	Prescriptive data of survivors and non-survivors as regards bacteriological diagnosis of pulmonary TB	106

# $\underline{\textit{List of tables}}$ (Cont.)

Table number	subject	Page
29	Comparison between survivors and non-survivors as regards to resistence to anti-TB drugs (MDR& XDR)	106
30	Comparison between survivors and non-survivors as regards to duration of treatment and treatment regimens	107
31	Risk factors for non-survival (Logistic regression model)	108
32	Performance of some suggested factors for prediction of non-survival	109
33	Value of some suggested factors for prediction of mortality	110
34	Value of female, renal impairement, far advanced lesion, mechanical ventilation and electrolytes disturbance for prediction of mortality	113

# List of figures

Table number	subject	Page
1	Egyptian mummy in the British Museum	4
2	Progress in applying the Task Force framework for assessment of TB surveillance data, July 2012	6
3	Fate of the studied cases	91
4	Comparison between survivors and non-survivors as regards to sex	92
5	Comparison between survivors and non-survivors as regards to mean blood pressure	95
6	Comparison between survivors and non-survivors as regards spread of pulmonary tuberculosis	96
7	Comparison between survivors and non-survivors as regards to type of respiratory failure	97
8	Comparison between survivors and non-survivors as regards to timing of ICU admission	99
9	Comparison between survivors and non-survivors as regards to GCS and APACHE II score on admission	100
10	Comparison between survivors and non-survivors as regards electrolytes disturbance	102
11	Comparison between survivors and non-survivors as regards to mean PH	105
12	ROC curve of some suggested factors for prediction of non-survival	109
13	Value of Albumin $\leq 2.6$ (gm/dl) for prediction of non-survival	110
14	Value of O2 saturation ≤ 85% for prediction of non- survival	111
15	Value of GCS ≤12.0 (Score) for prediction of non- survival	111

# $\underline{\textit{List of figures}}$ (Cont.)

Figure number	subject	Page
16	Value of Urea ≥55.0 (mg/dL) for prediction of non- survival	112
17	Value of Creatinine ≥1.5 (mg/dL) for prediction of non-survival	112
18	Value of APACHE II ≥26 (Score) for prediction of non-survival	113

#### List of A bbreviations

**β.** Regression coefficient

μ**g** Microgram

μl Microliter

**ADA** Adenosine deaminase

**AF** Atrial fibrillation

**AFB** Acid-fast bacilli

**AIDS** Acquired immunodeficiency syndrome

**APACHE II** Acute physiology and chronic health

evaluation II

**ARDS** Acute respiratory distress syndrome

**ARF** Acute respiratory failure

**ART** Antiretroviral therapy

**AUC** Area under curve

BCG Bacillus Calmette-Guérin

Cat I Category I

#### List of A bbreviations (Cont.)

Cat II Category II

Centers for disease control

**CDC** and prevention

**CDR** Case detection rate

**CI** Confidence interval

**CLD** Chronic liver diseases

**CMI** Cell-mediated immunity

Chronic obstructive **COPD** 

pulmonary disease

Co-trimoxazole preventive **CPT** 

therapy

**CRF** Chronic renal failure

**CT** Computed tomography

**CTP** Child-Turcotte-Pugh

**DA** Diagnostic accuracy

**DCL** Disturbed conscious lLevel

#### List of A bbreviations (Cont.)

**DBP** Diastolic blood pressure

**dl** Deciliter

**DM** Diabetes mellitus

**DNA** Double stranded nucleic acid

Directly observed treatment

**DOTS** strategy

**DST** Drug susceptiblity test

**DR** Drug resistant

**DRS** Drug resistance survey

**DVT** Deep venous thrombosis

**ESP** Extra-sensing power

GLC Green light committee

**GSC** Glasgow coma scale

**Hb** Hemoglobin

**HLA** Human leukocyte antigen

### $\underline{\textit{List of A bbreviations}} \text{ (Cont.)}$

**HIO** Health insurance organization

Human immunodeficiency

**HIV** virus

**HRCT** High resolution computed

tomography

**ICU** Intensive care unit

**IFN-**γ Interferon-gamma

Interferon-gamma release IGRA

assay

**INH** Isoniazid

**INR** International normalized ratio

**IPT** Isoniazid preventive therapy

**IQR** Inter-quartile range

**Kg** Kilogram

Multi-drug-resistant MDR-TB

tuberculosis

#### List of A bbreviations (Cont.)

Mg Milligram

Mycobacterial growth indicator MGIT

tube

MHD Maintenance haemodialysis

ml Milliliter

**mm** Millimeter

**mmol** Millimole

MOF Multiple organ failure

MTB Mycobacterium tuberculosis

MV Mechanical ventilation

National tuberculosis control **NTP** 

programme

**OR** Odd ratio

**PA** Posteroanterior

PAS Para-amino salicylic acid

**PCR** Polymerase chain reaction

**PNV** Predictive negative value

### $\underline{\textit{List of A bbreviations}} \text{ (Cont.)}$

**PPD** Purified protein derivative

**PPV** Predictive positive value

**PT** Prothrombin time

**PTT** Partial thromboplastin time

**RIF** Rifampicin

**RICU** Respiratory intensive care unit

**RNA** Ribonucleic acid

**RT** Renal transplantation

**SBP** Systolic blood pressure

**SD** Standard deviation

**SE** Standard error

Serum glutamate oxaloacetate
SGOT

transaminase

Serum glutamate pyruvate SGPT

transaminase

**SVT** Supra ventricular tachycardia

**TB** Tuberculosis